Decline in peripheral blood NKG2D+CD3+CD56+ NKT cells in metastatic colorectal cancer patients

Gharagozloo M1, Rezaei A1, Kalantari H2, Bahador A3, Hassannejad N4, Maracy M5, Nouri N6, Sedghi M7, Ghazanfari H1, Bayat B7

Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. hd.ghazanfari@gmail.com

ABSTRACT

OBJECTIVE: Colorectal cancer (CRC) is one of the main causes of cancer deaths in the world. This cancer can be divided into non-metastatic and metastatic CRC stages. CD3+CD56+ NKT cell subsets are a minor T cell subset in peripheral blood and allow the killing of tumor cells in direct manner. Little is obvious about levels and surface markers of these cells such as NKG2D in different cancers, especially in CRC.

METHODS: We included 15 non-metastatic (low-grade), 11 non-metastatic (high-grade), 10 metastatic colorectal cancer patients and 18 healthy controls. The percentages of CD3+CD56+ NKT cells and NKG2D+CD56+ NKT cells from samples were analyzed by flow cytometry in peripheral blood mononuclear cells (PBMCs) of samples.

RESULTS: We found that there was a significantly lower number of NKG2D+CD3+CD56+ cells in peripheral blood of patients with metastatic colorectal cancer compared with normal controls (77.53 ± 5.79 % vs 90.74 ± 9.84 %; p<0.01).

CONCLUSION: The fact that frequency of NKG2D+CD56+ NKT cells was significantly lower in patients with metastatic colorectal cancer compared to healthy controls strengthens the hypothesis that NKT cells can play a substantial role in the protection against human colorectal cancer, and this opens up avenues for novel studies about elucidating the other aspects of tumor surveillance in CRC progression and immunotherapy (Tab. 2, Fig. 2, Ref. 46).

KEY WORDS: low-grade non-metastatic colorectal cancer, high-grade non-metastatic colorectal cancer, metastatic colorectal cancer, CD3+CD56+ NKT cells, NKG2D.

Introduction

Colorectal cancer (CRC) is one of the main causes of cancer deaths in the world, especially in the developed countries. Based on TNM (Tumor/node/metastasis) system, this cancer can be divided into non-metastatic (I-III) and metastatic (IV) CRC stages (1). Similar to other cancers, a tumor can be classified as being of low or high grade (2).

Natural killer T (NKT) cells are innate-like T lymphocytes with unique activation and effector properties (3). The main features of NKT cells are co-expression of NK cell markers and T cell molecules (especially pan T cell marker CD3), CD1d restriction (4,5). Totally, NKT cells are divided into three subsets, namely type I NKT cells also called invariant (i) NKT cells, type II NKT cells, and type III NKT or NKT-like cells (6). Some experiments indicate that NKT cells generate antitumor activity in solid tumors and certain hematologic forms of cancer (7). Some of these reports suggest a protective role for iNKT and NKT-like cells compared to type II NKT cells showing to be majorly immunosuppressive (8,9). In general, iNKT cells were diminished significantly in solid tumors, and the low frequencies of peripheral blood iNKT cells associate with poor prognosis in plenty of cancers (10–12).

CD3+CD56+ NKT-like cells include roughly 5 to 15% of the peripheral T-cell pool. Owing to repeated exposure to antigen, these cells gently increase in absolute number in older persons but are absent in cord blood (1).

NKG2D (Natural Killer Group 2D; CD314) was found to be preferentially expressed by human natural killer (NK) cells, CD8+ T cells, and some auto-reactive CD4+ T cells (12–14). In NK cells, NKG2D functions as the primary activating receptor, while in T cells it acts as a co-stimulatory receptor that reinforces TCR-mediated activation (15–17). Consequently, NKG2D/NKG2DLs system may represent an important activation to begin a strong immune response to malignant cells (18). The NKG2D ligands (NKG2DLs) consist of a diverse array of proteins that are structurally related to MHC class I. The main targets recognized by NKG2D are MICA/B (MHC class I related molecules). NKG2D
ligands are extensively expressed on solid tumors and in some forms of leukemia (15). Hence, owing to the loss of these ligands in normal cells and their expression in some types of cell stress such as cancers, NKG2D is considered to be one of the molecules involved in immune surveillance, particularly in the early stage of tumor development (19–24). In other words, NKG2D and its ligands serve as a self-immunosensing system and alert for host immune defense in response to tumors (25).

The presence of MICs on many progressing neoplasms, including breast, lung, gastric, renal, colon, ovarian, and prostate carcinomas and melanomas, indicates that MIC expression on tumors could enhance the immune evasion (26). During cancer progression, the immune pressure on the tumor may end up in the selection of cells devoid of NKG2D ligands. Accordingly, in the affected persons, most primary tumors appear to express NKG2D ligands, whereas more advanced tumors and metastasis express low levels (27–29). This situation has been associated with the transacting effects of soluble MICs (sMICs) cleaved from solid tumors and leukemic cells by a tumor-related metalloproteinase (30–32), followed by down-regulation of NKG2D through promoting its internalization and lysosomal degradation on immune cells (30).

Also, NKG2D was expressed on the surface of a unique CD3+CD56+ NKT-like cell subset (12). CD3+CD56+ NKT-like cells are a minor T cell subset in the peripheral blood (<10%) and are at maximum in the liver (up to 30%) (33). Considerably, these cells conduct non-MHC-restricted and MHC-restricted lysis of tumor target cells in direct cell-killing manner and displayed robust antitumor activity in adoptive transfer investigations (34–38). To our knowledge, data demonstrated in our study regarding the NKG2D expression state on systemic NKT-like cells and frequency of these cells in non-metastatic and metastatic cancer patients are still lacking.

Materials and methods

Patients’ and controls’ samples

Heparinized peripheral blood was obtained from 36 patients with colorectal cancer attending the gastroenterology clinic of Al-zahra, khanevadeh, and seid-al-shohada hospitals, affiliated to Esfahan University of Medical Sciences, as well as 18 age- and sex-matched healthy volunteers. Written consent was obtained from all patients and healthy controls, and the study was approved by the Ethical Committee of Esfahan University of Medical Sciences, as well as 18 age- and sex-matched healthy volunteers. Written consent was obtained from all patients and healthy controls, and the study was approved by the Ethical Committee of Esfahan University of Medical Sciences. The disease diagnosis was based on the presence of symptoms of constipation in recent 6 months, history of familial polyposis, anus bleeding and positive colonoscopy results in relation to non-metastatic patients, and history of colorectal cancer with current tumor dissemination to other organs in metastatic patients. TNM system is applied to classify CRC in four stages (I, II, III, and IV). We used both WHO (low and high grades) and TNM systems for the grouping of patients as follows:
- Normal: healthy individuals
- Non-metastatic (low-grade): stages I & II
- Non-metastatic (high-grade): stage III
- Metastatic (distant metastasis): stage IV

Also, there is a checklist of histopathologic features to improve the standard of colorectal cancer reporting:

A: Histologic type assessed based on WHO classification as follows:
- Adenocarcinoma
- Mucinous adenocarcinoma
- Signet-ring cell carcinoma
- Small-cell carcinoma
- Squamous cell carcinoma
- Adenosquamous carcinoma
- Medullary carcinoma
- Undifferentiated carcinoma (2)

Peripheral blood mononuclear cell (PBMC) isolation

The most common method for PBMC isolation, Ficoll-Hypaque PBMC separation, was applied. Briefly, fresh peripheral whole-blood samples with heparin coagulant were diluted in one-to-one ratio with PBS/2 % FBS solution. Then, the diluted blood sample was laid gently on Ficoll-Hypaque layer (sigma, St Louis, MO, USA) and finally, PBMC was separated from this solution via density centrifugation at 2,800 rpm for 20 min. The viability of isolated cells was more than 95% as assessed by trypan blue exclusion test.

Flow cytometry

PBMC staining for FACS analysis was done with an optimized amount of the following fluorochrome conjugated mAbs: CD3-PerCp, CD56-FITC, NKG2D-PE, PerCp Mouse IgG1 κ Isotype Control, FITC Mouse IgG2b κ Isotype Control, and PE Mouse IgG1 κ Isotype Control. All mAbs with exception of NKG2D-PE and PE Mouse Isotype control (eBioscience; San Diego, CA; USA) were purchased from BD Bioscience (San Jose, CA, USA). The isolated cell suspension was adjusted at 10⁷–10⁸ cells/ml and incubated with anti CD3, anti CD56 and anti NKG2D for 30 min at 4°C. Simultaneously, daily, we incubated a tube with isotype controls for these three color stains. Ultimately, the cells were fixed with 0.5 % paraformaldehyde solution in case that evaluation is delayed. The three-color analysis on FACS caliber (BD) was used to demonstrate the NKG2D expression on CD56+CD3+ as NKT-like cells.

Statistics

Statistical analysis was performed using the SPSS19 statistical software. The results were evaluated by one-way ANOVA and Kruskal–Wallis tests. Probability values of less than 0.05 were regarded significant. The results presented in text, tables and figures represent mean standard deviation (SD).

Results

Characteristics of patients and healthy donors

Patients were classi...
In our study, 30 samples were from patients with adenocarcinoma, and 6 cases were classified as mucinous adenocarcinoma. Similarly to previous studies, in our study, other types of tumor were rare (2).

Frequency of CD3+CD56+ NKT-like cells in patients with colorectal cancer and normal subjects

Our results showed no statistically significant difference among metastatic or non-metastatic colorectal cancer patients and healthy controls.

Frequency of NKG2D+ NKT-like cells in the study groups

By three-color flow cytometry method, we found a significantly lower number of NKG2D+CD3+CD56+ cells in peripheral blood of metastatic colorectal cancer compared with normal controls (77.53 ± 5.79 % vs 90.74 ± 9.84 %; p < 0.01); nevertheless, no significant differences were observed between non-metastatic patients and healthy subjects (Tab. 2, Figs 1A and 2).

Mean fluorescence intensity (MFI) of NKG2D expression on peripheral blood CD3+CD56+ cells in the patients and normal groups

In agreement with the frequency of NKG2D+NKT-like cells, the MFI of NKG2D on these cells was significantly reduced in the metastatic patients in comparison to the normal group (37.94 ± 8.24 vs 50.36 ± 8.75; p < 0.005). Also, it was diminished less intensely in the non-metastatic (high-grade) patients compared with healthy controls (41.56 ± 7.99 vs 50.36 ± 8.75; p < 0.05) (Tab. 2, Figs 1B and 2).

---

**Tab. 1. Patient and healthy donor characteristics.**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Normal</th>
<th>Non-metastatic (low-grade)</th>
<th>Non-metastatic (high-grade)</th>
<th>Metastatic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>18</td>
<td>15</td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>8</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>10</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Age Minimum</td>
<td>29</td>
<td>40</td>
<td>43</td>
<td>44</td>
</tr>
<tr>
<td>Age Maximum</td>
<td>65</td>
<td>71</td>
<td>71</td>
<td>72</td>
</tr>
</tbody>
</table>

**Tab. 2. Mean frequency of CD3+CD56+ and NKG2D+CD3+CD56+cells and MFI of NKG2D on these cells in study groups.**

<table>
<thead>
<tr>
<th>%</th>
<th>Control</th>
<th>Non-metastatic (low-grade)</th>
<th>Non-metastatic (high-grade)</th>
<th>Metastatic</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3+CD56+ cells in lymphocytes</td>
<td>5.32±3.98</td>
<td>6.99±2.73</td>
<td>5.29±3.06</td>
<td>4.76±2.64</td>
<td>0.3</td>
</tr>
<tr>
<td>MFI of CD56 on CD3+CD56+ cells</td>
<td>52.36±14.96</td>
<td>48.42±20.40</td>
<td>40.27±19.36</td>
<td>48.85±17.69</td>
<td>0.38</td>
</tr>
<tr>
<td>NKG2D+CD3+CD56+ cells</td>
<td>90.74±9.84</td>
<td>86.31±9.64</td>
<td>82.74±12.39</td>
<td>77.53±5.79</td>
<td>0.009</td>
</tr>
<tr>
<td>MFI of NKG2D on NKG2D+CD3+CD56+ cells</td>
<td>50.36±8.75</td>
<td>46.95±8.32</td>
<td>41.56±7.99</td>
<td>37.94±8.24</td>
<td>0.002</td>
</tr>
</tbody>
</table>

The results represent mean percent (±SD) of the cells and MFI (±SD) of NKG2D expression on the related cells.

---

Fig. 1. A) Frequency (= percentage) of circulating NKG2D+ NKT-like cells, and B) Mean fluorescence intensity (MFI) of NKG2D expression on circulating NKT-like cells in the study patients vs normal controls. Significant p (p < 0.05 or less) values are shown in both A & B.
Discussion

Despite representing a small portion of systemic lymphocytes, CD3+CD56+ NKT-like cells show strong antitumor activities in vitro and in vivo through direct cell killing combined with other unique abilities to mediate immune cell recruitment and proliferation (39). In the study, we enumerated circulating CD3+CD56+ NKT-like cells; but the obtained data did not show any significant differences among frequencies of these cells in the study groups (Tab. 2). Besides NKT-like cells, a small proportion of Type I NKT (iNKT) cells are CD56+ (40, 41). The discrimination between these two (iNKT & NKT-like) subsets requires the use of CD1d loaded with α-GalCer (α-galactosylceramide) (42), lacking in our research. Thus, at this level, we could not determine the type of NKT cells in the patients and controls, and so we reported our results as CD3+CD56+ NKT cells.

Jadidi et al. showed that the amount of NKT-like cells in patients with CLL was significantly lower in comparison to healthy subjects and was inversely correlated with Treg cell proliferation and disease progression (43). It has already been demonstrated that Treg cells can suppress the proliferation, cytokine release and cytotoxic activity of NKT cells (44). However, in spite of increasing Treg cell levels in CRC, the role of these cells in CRC is currently under debate. For example, Blatner et.al displayed that in both human CRC and murine polyposis, the interaction between mast cell and Treg cell contributes to systemic regulatory T cell dysfunction, and switches from suppressing to generating potently immune suppressive, but proinflammatory Treg cells (ΔTreg) (45) and this may be a convincing reason for our results about frequency of CD3+CD56+ NKT cells contrary to the other tumor studies.

One of the important mechanisms employed by many cancers such as colon carcinoma, to promote immune evasion is the release of soluble forms of NKG2D ligands such as MICs, and consequential down-regulation of NKG2D expression with severe defects in cytotoxic activities of CD3+CD56+ NKT-like cells similar to NK and CTLs (32, 39, 46). Regarding the lack of previous data about colorectal cancer, in this work, we indicated...
that the frequency of systemic CD3+CD56+ NKT cells and NK-G2D expression on these cells decrease during the progression of colorectal cancer, especially in metastatic patients (Fig. 1 and Tab. 2). CD3+CD56+ NKT-like cells have been reported to induce NK-sensitive target U937 cell and NK-resistant Raji cell lysis in a non-MHC-restricted manner (2); whether NK-G2D is engaged in the cell killing induced by CD3+CD56+ NKT-like cells remains unknown. The results of Wang et al. implied that the NK-G2D receptor plays a fundamental role in cytolyis of ovarian and prostate cancer cells by CD3+CD56+ NKT-like cells, and this killing mediated by NK-G2D is independent of TCR stimulation (39). The underlying mechanism has been associated with the trans-acting effects of sMICs cleared from solid tumors and leukemic cells by a tumor-related metalloproteinase (31, 32). The engagement of sMICs then promotes NK-G2D internalization and degradation in NK cells and T cells. Although, we did not assess the circulating MICs levels in study groups to determine the correlation between ligands and lower NK-G2D expression on CD56+NKT cells in colorectal cancer, there are some documents consistent with these findings that the induction or upregulation of MICs may promote tumor surveillance by engaging the activating receptor NK-G2D on CD56+NKT-like cells in leukemia patients and solid tumors. Also, there is evidence that the most important membrane-bounded NK-G2D ligand (MICA) was prevalent only in low-grade cancers and may be released into the tumor stroma and circulation in high-grade cancers as sMICA (soluble MICA) (46).

In conclusion, based on the fact that the frequency of NK-G2D+CD56+ NKT cells and MFI of NK-G2D expression on these cells were significantly lower in patients with metastatic colorectal cancer compared to healthy controls, it appears that sMICs may impact all NKG2D+ lymphocytes such as CD3+CD56+ NKT cells in colorectal cancer and this opens up avenues of approach for novel studies about elucidating the other aspects of tumor surveillance in CRC progression and immunotherapy.

References


Received August 10, 2017. Accepted August 16, 2017.